Apellis Pharmace Stock Price, News & Analysis

Apellis Pharmaceuticals (Nasdaq: APLS) plans to host a conference call and webcast on August 9, 2021, at 4:30 p.m. ET to discuss its second quarter 2021 financial results. Participants can join via phone or through the company’s website. A 90-day replay of the webcast will be accessible post-event. Apellis focuses on targeted C3 therapies and aims to develop transformative treatments for diseases driven by excessive complement activation. More information is available at www.apellis.com.

Apellis Pharmaceuticals (Nasdaq: APLS) has successfully closed privately negotiated exchange transactions for its 3.500% Convertible Senior Notes due 2026. Approximately $201.1 million of these notes were exchanged, resulting in the issuance of 5,992,217 shares of common stock. The shares are unregistered under current securities laws and cannot be sold in the U.S. without proper registration or exemption. This strategic move aims to strengthen the company's financial position and support its ongoing commitment to developing targeted C3 therapies for various debilitating diseases.

Apellis Pharmaceuticals (Nasdaq:APLS) announced it has engaged in privately negotiated exchange agreements with holders of its 3.500% Convertible Senior Notes due 2026. The holders have agreed to exchange approximately $198.6 million of the Notes for 4,530,431 shares of common stock, equating to 22.8065 shares per $1,000 of Notes. An additional number of shares will be issued based on the average stock price over a specified period. The exchange transactions are expected to close by July 23, 2021, pending customary closing conditions.

Apellis Pharmaceuticals (APLS) announced equity awards to a new employee, consisting of options for 8,000 shares and 4,000 restricted stock units (RSUs). The options have an exercise price of $67.80, matching the closing stock price on the grant date of July 1, 2021. The vesting schedule sets forth that one-fourth of the options will vest after one year, with the remainder vesting monthly over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and supports the company’s efforts in attracting talent for its targeted C3 therapies.

Apellis Pharmaceuticals (Nasdaq: APLS) and Beam Therapeutics (Nasdaq: BEAM) announced a five-year exclusive collaboration focused on base editing technology to develop treatments for complement-driven diseases. The partnership will target six research programs directed at the eye, liver, and brain, utilizing Beam's technology for precision gene editing. Apellis will lead the development of licensed programs and has committed $75 million, with further milestone payments possible. This strategic alliance aims to enhance Apellis' leadership in complement therapeutics and expand treatment options for patients.

Apellis Pharmaceuticals (Nasdaq: APLS) will host a Research and Development Day on June 30, 2021, from 12:30 p.m. to 4:30 p.m. ET in New York City and online. The event will showcase the company’s expanding pipeline in rare diseases, ophthalmology, and neurology. Key opinion leaders from top institutions will participate, including experts from Fondazione IRCCS and the Montreal Neurological Institute. A live webcast and presentation will be available on Apellis’ website, with a replay accessible for 90 days post-event.

Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in two upcoming investor conferences. The Goldman Sachs Healthcare Conference will feature a fireside chat on June 10, 2021 at 8:00 a.m. ET, while the Bank of America Napa Biopharma Conference is set for June 16, 2021 at 4:30 p.m. ET. Both events will be available via live webcast and can be accessed from the company’s investors and media page. Replays will be accessible for 90 days post-event.

Apellis focuses on pioneering targeted C3 therapies for various diseases.

Apellis Pharmaceuticals (APLS) reported positive results from the Phase 3 PRINCE study of EMPAVELI™ (pegcetacoplan) for treating paroxysmal nocturnal hemoglobinuria (PNH) in treatment-naïve adults. The study showed statistical superiority in hemoglobin stabilization (86% vs. 0%, p<0.0001) and significant reduction in lactate dehydrogenase (90% decrease) compared to standard care. Mean hemoglobin levels rose from 9.4 to 12.1 g/dL in the EMPAVELI group. Additionally, 91% of EMPAVELI patients remained transfusion-free. The safety profile was consistent with previous studies, with serious adverse events being lower than standard care.

Apellis Pharmaceuticals announced FDA approval of EMPAVELI™ (pegcetacoplan), a groundbreaking targeted C3 therapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). This therapy is approved for treatment-naïve patients and those switching from C5 inhibitors like Soliris® and Ultomiris®. In the pivotal Phase 3 PEGASUS study, EMPAVELI demonstrated superiority over Soliris in increasing hemoglobin levels and a significant 85% of EMPAVELI patients were transfusion-free at Week 16. However, EMPAVELI carries a boxed warning for serious infections, necessitating vaccinations before treatment.